Relay Therapeutics has announced encouraging interim results for RLY-2608, the initial investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα.

These findings showcase the efficacy of its innovative EVX-B2 mRNA Gonorrhea vaccine candidate in eradicating gonorrhea bacteria through the induction of a specialized immune response.

Terns Pharmaceuticals Reports Successful Phase 1 Results for TERN-601 Daily Oral GLP-1R Agonist in Obesity Treatment.

The IDeate-Lung01 Phase 2 Trial shows Ifinatamab Deruxtecan maintains encouraging objective response rates in patients with advanced-stage small cell lung cancer.

GSK plc (LSE/NYSE: GSK) released encouraging top-line outcomes from MATINEE in adult patients suffering from chronic obstructive pulmonary disease (COPD).

Ventyx Biosciences announced that the initial patient has been administered a dose in a Phase 2a study of VTX3232 for individuals with early-stage Parkinson’s disease.

Cytonics Completes Phase 1 Enrollment for Study on CYT-108, a New Protease Inhibitor, in Knee Osteoarthritis Patients.

Huonslab Reveals Favorable In Vivo PK Study Outcomes for Trastuzumab/HyDIFFUZETM vs. Commercial rHuPH20 and Trastuzumab Co-formulation.

NextPoint Therapeutics Reveals NPX372, a Novel Drug Targeting B7-H7 in Solid Tumors, as New T Cell Engager.

Medigene Gets U.S. FDA Approval for IND of MDG1015, a Novel Third Gen T Cell Therapy Targeting Various Solid Tumors.

Boehringer Ingelheim reveals intention to progress a promising new therapy for Geographic Atrophy, inspired by favorable Phase I outcomes.

In a pioneering fixed dose study, weekly insulin efsitora alfa achieves A1C reduction comparable to that of daily insulin.